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Abstract
Background: Cognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect
their quality of life. So far, the best cognitive treatment options for MS patients are a matter of debate. Therefore, this
study aims to investigate the effectiveness of two promising non-pharmacological treatments: cognitive rehabilitation
therapy (CRT) and mindfulness-based cognitive therapy (MBCT). Furthermore, this study aims to gain additional
knowledge about the aetiology of cognitive problems among MS patients, since this may help to develop and guide
effective cognitive treatments.
Methods/design: In a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised
into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a
structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be
performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the
level of subjective cognitive complaints. Secondary outcome measures are objective cognitive function, functional
brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and
daily life functioning.
Discussion: To our knowledge, this will be the first RCT that investigates the effect of MBCT on cognitive function
among MS patients. In addition, studying the effect of CRT on cognitive function may provide direction to the
contradictory evidence that is currently available. This study will also provide information on changes in functional
brain networks in relation to cognitive function. To conclude, this study may help to understand and treat cognitive
problems among MS patients.
Trial registration: This trial was prospectively registered at the Dutch Trial Registration (number NTR6459, registered
on 31 May 2017).
Keywords: Multiple sclerosis, Cognition, Cognitive rehabilitation therapy, Mindfulness-based cognitive therapy, Brain
networks, Randomised controlled trial
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Background
Multiple sclerosis (MS) is a chronic disease of the central
nervous system, which leads to physical, neuropsychiatric
and cognitive problems. Cognitive problems are commonly
reported by MS patients, with prevalence rates of objective
cognitive deficits varying between 43 and 70% [1]. The
most frequently affected cognitive domains are information
processing speed, memory, attention, visuospatial process-
ing and executive function. These objective cognitive defi-
cits (i.e. assessed with cognitive tests) only show a weak
relation with the cognitive complaints reported by MS
patients themselves [2, 3]. Despite this weak relation, sub-
jectively experienced cognitive problems are arguably as
important as objective cognitive deficits, since they may re-
flect the burden of cognitive problems in daily life.
The impact of cognitive problems on daily life can be
extensive given the relatively young age of disease onset.
Problems in social relations and work participation are
likely to occur, consequently negatively affecting the
quality of life of MS patients [1, 4]. This highlights the
need for effective cognitive treatment options for MS pa-
tients. To develop and guide effective cognitive treat-
ments, knowledge about the aetiology of objective and
subjective cognitive problems is essential.
Aetiology of cognitive problems
The aetiology of objective and subjective cognitive prob-
lems in MS is complex and not completely understood.
Objective cognitive deficits in MS patients have been
linked to cortical, deep grey matter and white matter
damage [5, 6]. Researchers have argued that this wide-
spread pathology may result in a disruption of the con-
nectivity between brain regions, which in turn may
result in cognitive decline [7]. Changes in brain net-
works are indeed present in MS patients: studies have
reported changes in functional connectivity [7] and a
loss of hierarchal structure [8], which both related to re-
duced objective cognitive performance in MS patients.
Whereas the aetiology of objective cognitive deficits is
widely studied, studies focusing on the aetiology of subjective
cognitive complaints are rare. Since subjective and objective
cognitive problems correlate weakly [2, 3], their aetiology
might be different [9]. One recent study found that subject-
ively experienced cognitive problems could not be explained
by brain pathology, but no measures of brain networks were
included [9]. To date, the study of brain networks and their
relation to objective and subjective cognitive function among
MS patients is still in its infancy. Additional well-designed
studies are needed to unravel the aetiology of objective and
subjective cognitive problems in MS.
Treatment of cognitive problems
The best cognitive treatment options for MS patients are still
a matter of debate [10]. A promising non-pharmacological
treatment option is cognitive rehabilitation therapy (CRT)
[10]. CRT entails the learning of new cognitive strategies
aimed at compensating for cognitive problems. The use of
these strategies shows positive effects on cognitive function
among stroke and brain injury patients [11]. There is also
some evidence for positive effects of CRT on cognitive func-
tion among MS patients. However, no final conclusion on
the effectiveness of CRT can be established due to contra-
dictory findings [12, 13]. These contradictory findings may
be explained by small sample sizes, heterogeneous interven-
tions across studies and methodological limitations (e.g.
biased selection) [12, 13].
A second promising non-pharmacological treatment
option is mindfulness-based cognitive therapy (MBCT)
[14]. MBCT entails mindfulness training combined with
elements of cognitive behavioural therapy. There is prelim-
inary evidence that mindfulness-based interventions posi-
tively affect cognitive function in healthy individuals
[14, 15] and they may even influence brain structures
and functions that are involved in cognitive function
[14, 16, 17]. In MS patients, positive effects of mind-
fulness-based interventions on psychological symptoms
have been found [18–20], and a recent pilot study re-
ported some positive effects of mindfulness on objective
cognitive function [19]. To our knowledge, no other stud-
ies have investigated the effect of mindfulness-based inter-
ventions on cognitive function among MS patients. In
summary, well-designed studies are necessary to investi-
gate the effect of MBCT and CRT on cognitive function
among patients with MS.
The REMIND-MS study
The REMIND-MS study is a randomised controlled trial
(RCT) that investigates the effect of CRT and MBCT on
subjective and objective cognitive function in MS pa-
tients. Additionally, resting-state magnetoencephalogra-
phy (MEG) data will be obtained to gain additional
knowledge about the aetiology of subjective and object-
ive cognitive problems with respect to functional brain
networks, and to unravel if cognitive improvements after
both interventions are associated with functional brain
network changes.
Objectives
This study primarily aims to examine the effectiveness
of CRT and MBCT on subjectively experienced cognitive
problems among MS patients. We hypothesise that both
CRT and MBCT positively affect subjective cognitive
function compared to enhanced treatment as usual
(ETAU). We also expect positive effects on the second-
ary outcome measures objective cognitive function,
functional brain network measures, psychological symp-
toms, well-being, quality of life and daily life functioning.
Additionally, we will evaluate in an exploratory way
Nauta et al. BMC Neurology  (2017) 17:201 Page 2 of 10
whether there are differences in intervention effects be-
tween CRT and MBCT.
Secondary study objectives are:
1) to explore the role of functional brain network
measures (using MEG) in subjective and objective
cognitive problems, and to evaluate whether there
are differences in functional brain network measures
between these types of cognitive problems;
2) to explore the role of functional brain network
measures as possible mediators in the effect of the
interventions;
3) to evaluate whether alterations in objective cognitive
function, functional brain network measures,
psychological symptoms, well-being, quality of life
and daily life functioning are mediating factors that
determine subjective cognitive function;
4) to evaluate which factors determine whether a
patient is likely to benefit from one of the therapies,
such disease severity, severity of cognitive problems
and mood at baseline, or gender.
Methods-design
Design
The REMIND-MS study is a dual-centre, single-blind
RCT with three parallel groups: CRT, MBCT and ETAU.
All interventions last nine weeks in total. Measurements
take place at baseline, post-intervention and after a 6-
month follow-up period. The full trial design is sum-
marised in Fig. 1.
Setting
Selection and measurements take place at the VU Univer-
sity Medical Center in Amsterdam, the Netherlands. Part of
the measurements, that is, the self-report questionnaires,
can be completed by the participants at home. The inter-
ventions take place at two centres in the Netherlands: VU
University Medical Center in Amsterdam and Klimmendaal
Rehabilitation Center in Arnhem.
Participants
Recruitment and consent
Participants are recruited through the participating cen-
tres (VU University Medical Center and Klimmendaal Re-
habilitation Center), the ‘VUmc MS Center Amsterdam’
website and MS patient associations. All potentially eli-
gible participants who express interest in the study are
provided with written trial information, which contains
information about the rationale, purpose and personal
implications of the study. The information sheet also
includes contact details of the trial coordinator and of an
independent medical doctor who is not part of the
research team, who can both be contacted for additional in-
formation. After sufficient time for consideration, potential
participants who are still interested to participate are in-
vited by the trial coordinator to sign the informed consent
form. After signing the informed consent form, it will be
checked whether the participants are fully eligible.
On the informed consent form, participants have the op-
tion to give permission for an informant to be contacted. If
permission is given, an informant of the participants will
also receive written information and an informed consent
form, as informants will be asked to complete one ques-
tionnaire at three time-points (see outcome measures). On
the informed consent form, participants and their infor-
mants also have the option to give permission for using
their data for other research, for sharing their data with re-
searchers outside of the European Union and to be con-
tacted again for follow-up research.
Inclusion criteria
Participants are eligible to participate if they meet the
following criteria: (1) between 18 and 65 years of age, (2)
confirmed diagnosis of MS according to the McDonald
2010 criteria [21], (3) a minimum score of 23 on the
Multiple Sclerosis Neuropsychological Questionnaire –
Patient version (MSNQ-P), which measures subjective
cognitive complaints [22].
Exclusion criteria
Participants who meet any of the following criteria are
excluded from participation: (1) psychosis, (2) suicidal
ideation, (3) an inability to speak or read Dutch, (4) pre-
vious experience with a similar intervention (e.g. a com-
parable cognitive rehabilitation training or mindfulness
training), (5) physical or cognitive disabilities, comorbid-
ities or treatments that would interfere too much with
the interventions to enrol in this study (to be evaluated
on an individual level). The reasons for excluding partic-
ipants who express interest in the study will be accur-
ately documented.
Sample size calculation
Mixed model analyses will be applied with three mea-
surements comparing two groups (MBCT vs. ETAU,
CRT vs. ETAU). There are no previous studies with MS
patients that investigated the effect of CRT or MBCT on
the primary outcome measure, the Cognitive Failure
Questionnaire (CFQ) [23]. Based on a previous RCT
using a comparable outcome measure, a medium effect
size can be expected [24, 25]. With an alpha of .05, a
power of .80, an intra-class correlation of .06, and 33
participants per group, a minimal difference of 0.62 SD
can be detected between two groups. Taking into ac-
count drop-out and loss to follow-up, we intend to re-
cruit 40 MS patients per group.
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Interventions
All interventions last nine weeks. The CRT consists of
nine 2.5-h group sessions, MBCT of eight 2.5-h group
sessions and one ‘silent day’, and enhanced treatment as
usual (ETAU) of one individual appointment within the
9-week period. For CRT and MBCT, the optimal group
size was determined based on previous experiences.
Groups will consist of a maximum of 6 people in the
CRT group and a maximum of 10 people in the MBCT
group. Professionally trained psychologists will guide the
CRT sessions, certified mindfulness trainers will teach
the MBCT sessions and MS specialist nurses will have
appointments with participants from the ETAU group.
All trainers will be instructed and supervised by the
same specialists. The interventions will be provided in a
standardised manner using a written protocol. The
trainers are instructed not to disclose treatment infor-
mation to trainers from another treatment arm. All par-
ticipants will receive an information brochure on MS
and cognition.
Cognitive rehabilitation therapy (CRT)
The CRT protocol focuses on the following cognitive do-
mains: speed of information processing, memory, execu-
tive function and mental fatigue. Cognitive impairments
will be treated by a combination of compensatory strategy
training and psycho-education. The proposed strategies
are based on MS-tailored variants of evidence-based treat-
ments that have been developed in CRT research with
brain-injured subjects. Treatment of problems in informa-
tion processing speed will be based on ‘Time Pressure
Management’ [26, 27], memory on ‘Training Memory
strategies’ [28], executive function on a ‘Multifaceted
Treatment for Executive Dysfunction’ [29, 30] and mental
fatigue on ‘Cognitive and Graded Activity Training’
[31, 32]. These four treatments are incorporated in the
protocol as described by Geusgens, Baars-Elsinga, Visser-
Meily and van Heugten [33]. In addition to cognitive strat-
egy training, CRT focuses on emotional and behavioural
changes, and grief resolution. Grief resolution will be in-
cluded by explaining the stages of bereavement and by
VUmc: eligibility check
Decision which location: VUmc or KR 
VUmc: randomisation
t = 9 
weeks 
MBCTCRT ETAU
VUmc: Baseline assessment
KR: randomisation
MBCTCRT ETAU
VUmc: Post-intervention assessment
VUmc: 6-month follow-up assessment
Lost to follow-up or discontinued 
Informed consent
Information provided
Excluded: no 
longer willing 
to participate
Excluded: based 
on in- and 
exclusion criteria
Confirm willingness to participate 
Excluded: no 
informed 
consent
Fig. 1 Flowchart of the trial design. KR = Klimmendaal Rehabilitation Center; VUmc = VU University Medical Center
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discussing the loss of physical independence, mobility, cog-
nitive ability and emotional control on self-esteem and fu-
ture perspective. The participants will receive homework
assignments aimed at identifying their own cognitive prob-
lems and at applying the learned strategies in daily life situ-
ation. These homework assignments will take 30 to 45 min
a day, 6 days per week.
Mindfulness based cognitive therapy (MBCT)
The MBCT protocol is primarily based on the MBCT
program by Segal, Williams and Teasdale [34]. MBCT is an
intervention in which aspects of mindfulness meditation
are combined with aspects of cognitive behavioural therapy.
MBCT focuses on increasing awareness of the present mo-
ment. To achieve this, participants will be trained in both
self-regulation of attention and non-judgmental awareness
of moment-to-moment experience. Patients will become
more aware of their emotions, thoughts and behaviours
and will learn to use more adaptive behaviour to respond
to their symptoms. The program will be adapted to the MS
patients in terms of tailoring psycho-educative elements to
themes relevant to the MS patient (e.g. cognitive problems)
and modified movement exercises (for patients suffering
from physical impairments). Participants will receive guided
mindfulness meditation exercises of 30 to 45 min, 6 days
per week, for home practice and a reader with home prac-
tice instructions and background information. All thera-
pists will fulfil the advanced criteria of the Association of
Mindfulness Based Teachers in the Netherlands and
Flanders, which are in concordance with those of the UK
Mindfulness-Based Teacher Trainer Network [35].
Enhanced treatment as usual (ETAU)
Enhanced treatment as usual (ETAU) entails an appoint-
ment with an MS specialist nurse in addition to usual
care. The appointment will focus on psycho-education.
More specifically, the MS specialist nurse will provide the
participants with information on the frequently affected
cognitive domains in MS and their relation to brain path-
ology. This will occur in a standardised manner.
Teacher ratings
CRT and MBCT sessions will be recorded on video to
evaluate teacher competence and protocol adherence.
These video recordings will solely be used for the pur-
pose of trainer evaluation, and the camera will be di-
rected at the trainer. For the CRT sessions, adherence to
the protocol will be checked using a checklist. For the
MBCT sessions, the Mindfulness-Based Interventions -
Teachers Assessment Criteria [36] will be used.
Adherence
For all groups, attendance to the sessions will be docu-
mented. For the CRT group, adherence to homework
assignments will be checked and evaluated during each
visit of the treatment period. For the MBCT group, ad-
herence will be assessed during the entire treatment
period with a calendar on which participants fill out
whether they adhere to both formal (e.g. the sitting
meditation) and informal (e.g. 3-min breathing space)
mindfulness exercises.
Replacement and follow-up of withdrawn participants
Participants can leave the study at any time for any reason
without any consequences. Follow-up measurements will
still be scheduled if the participant is willing and able to
participate in follow-up measurements. There will be no
replacement of individual participants after withdrawal. If a
high rate of participants drops out during the study, more
participants will be included in the study. These partici-
pants will be randomly allocated to one of three parallel
groups using the randomisation and minimisation proced-
ure as described under ‘randomisation and blinding’.
Relevant concomitant care and interventions
During the intervention period and the 6-months follow-
up period, patients are asked not to follow an intervention
outside this study that focuses on mindfulness or cogni-
tion, and to keep their level of care constant during this
period when possible. Naturally, usual care should con-
tinue, as do new treatment options when the health situ-
ation of the patient changes.
Demographic and patient characteristics
At baseline, the following demographic characteristics
are collected: age, gender, work status and education. In
addition, the following clinical characteristics will be
noted: comorbid condition as defined by the Cumulative
Illness Rating Scale (CIRS) [37], subtype of MS, year of
diagnosis, disease duration and MS disability as defined
by the Expanded Disability Status Scale (EDSS) [38]. If
an EDSS score is not available, or if this score has been
determined more than three months ago, a new EDSS
score will be gathered at baseline. The use of medication
will be noted at each assessment. Health care consump-
tion will be measured with a questionnaire on healthcare
utilisation and productivity losses in patients with a psy-
chiatric disorder (TIC-P) [39] and will be administered
at each measurement. Table 1 presents an overview of
the demographic and patient characteristics that will be
collected at each assessment.
Outcome measures
All outcome measures will be administered at each as-
sessment: at baseline, post-intervention and 6-months
follow-up (see Table 1).
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Primary outcome measure
The primary outcome measure is the level of subjective
cognitive complaints and is measured with the CFQ
[23]. Subjective cognitive complaints in terms of execu-
tive function will be measured with the Behaviour Rating
Inventory of Executive Function – Adult Version
(BRIEF-A) [40]. The BRIEF-A consists of a self- and an
informant report version.
Secondary outcome measures
Cognitive function A test battery based on the Minimal
Assessment of Cognitive Function in MS (MACFIMS) will
be used [41]. Verbal learning and memory is assessed with
the Dutch version of the California Verbal learning Test
(CVLT) [42]. Spatial learning and memory are measured
with the Brief Visuospatial Memory Test-Revised (BVMT-
R) [43]. Visual-spatial abilities are measured with the
Benton Judgment of Line Orientation Test (JLO) [44].
Visual processing speed and working memory are mea-
sured with the Symbol Digit Modalities Test (SDMT) [45].
Verbal fluency and memory retrieval are assessed with the
Controlled Oral Word Association Test (COWAT) [46].
Higher executive function is measured with the Delis-
Kaplan Executive Function System sorting test (D-KEFS)
free sorting condition [47]. Selective attention and response
inhibition are measured with the Stroop Colour-Word
Test [48]. When available, parallel versions of tests
will be administered for repeated assessment to ac-
count for material-specific learning effects.
Functional brain networks Resting-state MEG data will
be recorded using a 306-channel whole-head MEG
system (Elekta Neuromag Inc., Helsinki, Finland) in a
magnetically shielded room (Vacuumschmelze GmbH,
Hanau, Germany) at the VU University Medical Center.
Magnetic fields will be recorded during resting state (i.e.
a no-task, eyes-closed condition). Pre-processing of data
and removal of noise will be done on Linux computers
with available scripts [49]. The MEG data will be used to
determine resting-state functional connectivity and brain
network organisation. To study functional connectivity,
synchronisation measures will be computed, such as the
phase-lag index [7, 50]. To study brain network organ-
isation, tools from modern network theory will be ap-
plied to the entire network and a subset of the network
(i.e. the minimum spanning tree (MST)) [8, 50]. Mea-
sures such as degree, clustering coefficient and path
length will be computed, as well as MST-network de-
rived measures, such as betweenness centrality, tree
hierarchy and eccentricity. There will be an emphasis on
node centrality measures to identify the ‘hubs’ (i.e. highly
connected nodes) of the network [51]. Since the field of
modern network science is constantly developing, the
best methods and measures will be selected once the
study is completed.
Psychological symptoms Depression and anxiety are
measured with the Hospital Anxiety and Depression
Scale (HADS) [52]. The level of fatigue is measured with
the Checklist Individual Strength-20-r (CIS-20-r) [53].
The tendency to ruminate when being sad or depressed
is measured with the subscale ‘brooding’ of the Dutch
Ruminative Response Scale (RRS-NL) [54].
Quality of life Health-related quality of life is measured
with the Multiple Sclerosis Quality of Life Questionnaire
(MSQoL-54) [55].
Well-being Emotional, psychological and social well-
being is measured with the Mental Health Continuum-
Short Form (MHC-SF) [56]. The ability to be mindful, that
is, non-judgmental awareness of moment-to-moment
experience, is measured with the Five Facets of the Mind-
fulness Questionnaire short form (FFMQ-SF) [57]. Self-
compassion, that is, the ability to act with compassion
towards oneself in difficult times, is measured with the
short form of the Self-Compassion Scale (SCS-SF) [58].
Table 1 Overview of outcome measures per assessment
Assessment Baseline Post-intervention Follow-up
Demographic characteristics X
Medical history (e.g. MS subtype) X
Use of medication X X X
Expanded Disability Status Scale (EDSS) X
Health care consumption X X X
Questionnaires measuring subjective cognitive complaints, psychological
symptoms, quality of life, well-being and daily life functioning
X X X
Neuropsychological assessment X X X
Magnetoencephalography (MEG) X X X
Qualitative data to improve the interventions X
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Daily life functioning Participation in society is mea-
sured with the Utrecht Scale for Evaluation of Rehabili-
tation – Participation (USER-P) [59]. Goal Attainment
Scaling (GAS) is used to determine the effect of the
treatment on personalised goals in daily situations [60].
Randomisation and blinding
Following baseline assessment, participants will be ran-
domly allocated to one of three treatment arms (MBCT,
CRT or ETAU). First, the location of the intervention
will be determined based on the patient’s living location
and preference. For each location, randomisation will be
performed in variable blocks of 6 and 9, and with an
1:1:1 allocation ratio. A minimisation program will be
used to ensure balance between all groups. Minimisation
will be performed on three factors: (1) subjective cogni-
tive function, (2) age and (3) gender. Weighting is equal
for each factor. The minimisation program will be con-
structed before the start of the study by an independent
scientific programmer. The randomisation procedure
will be performed by a researcher who is not involved in
administering any outcome measure. Outcome measure-
ments will be administered by assessors who are blind to
treatment assignment, but this blinding is not feasible
with regard to participants and therapists. Prior to each
post-measurement, participants will be reminded not to
disclose their group allocation to the assessor.
Data management
The collected data will be labelled with a participant
identification code. The name and other identifiers of
the participant will be removed from the data. The link
between the participant identification code and the
names of the participants will be kept separately. An
electronic case report form is developed according to
the guidelines of Good Clinical Practice (GCP) to docu-
ment the data collected in the study. This case report
form will include demographic and clinical characteris-
tics, and all outcomes of the study parameters. The data
will be treated confidentially and will only be available to
the trial coordinator and principal investigator. Other in-
vestigators can only get access to the data for the pur-
pose of research and with permission of the principal
investigator. The data gathered in this study will be pro-
tected in accordance with the Dutch Personal Data Pro-
tection Act and the Medical Treatment Contracts Act.
Statistical analysis
Descriptive statistics
Data on demographic and clinical characteristics will be
summarised in a table. For adherence and other feasibility
indicators, frequencies and percentages will be calculated.
Satisfaction with the program will be summarised in quali-
tative descriptions. Differences between groups (CRT vs.
ETAU, MBCT vs. ETAU, CRT vs. MBCT, drop-outs vs.
treatment completers) in demographic and clinical charac-
teristics and outcome measurements at baseline are
analysed using independent samples t-tests (normally dis-
tributed continuous outcome variables), Mann-Whitney
U tests (skewed continuous outcome variables) and
Pearson’s chi-square tests (categorical outcome variables).
Primary and secondary objectives
To evaluate the effectiveness of the interventions,
mixed-model analyses will be performed for the primary
and secondary outcome measurements with time (base-
line, post-intervention, follow-up) as a within subjects fac-
tor and condition (CRT vs. ETAU, MBCT vs. ETAU, and
exploratory: CRT vs. MBCT) as a between-subjects factor.
These analyses will be performed using an intention-to-
treat approach, including all randomised participants re-
gardless of adherence and measurement completion.
Secondarily, per-protocol analyses will be performed for
further exploration of the intervention effects.
To evaluate the secondary study aims, mediation and
moderation analyses [61] will be performed to evaluate
whether alterations in functional brain networks play a
role in the effect of the interventions. In addition, cross-
sectional associations between functional brain networks
and cognitive function (subjective and objective) will be
analysed using Pearson’s correlation and linear regression
analyses. To evaluate whether alterations in secondary
study parameters are mediating factors that determine
subjective cognitive function, mediation analyses [61]
and linear regression analyses will be performed. Fi-
nally, logistic and linear regression models will be per-
formed to evaluate which factors determine whether a
patient is likely to benefit from one of the therapies.
For all analyses, confounding variables will be inserted,
such as age and education. Bonferroni corrections will
be applied to correct for multiple comparisons within
each objective.
Monitoring and harms
An independent monitor, the Clinical Research Bureau
(CRB) of the VU University Medical Center, will monitor
the data of this study according to GCP. The CRB will
check the following aspects of the participants: (1) in-
formed consents, (2) source data verification, (3) the re-
ported (serious) adverse events ((S)AEs). Considering the
nature of this study, SAEs are not expected. All AEs that
are reported spontaneously by the participant or observed
by the research staff or therapists will be recorded. All
SAEs will be reported by the investigator to the sponsor,
and the sponsor will inform the accredited Medical Ethics
Committee (MEC).
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Discussion
The best treatment options for cognitive problems in
MS patients are still a matter of debate. This study will
therefore investigate the effect of two promising non-
pharmacological treatments: MBCT and CRT. To our
knowledge, this will be the first RCT that investigates
the effect of MBCT on cognitive function among MS
patients. In addition, studying the effect of CRT on cog-
nitive function may provide direction to the contradict-
ory evidence that is currently available [12, 13]. If these
treatments appear to be effective, we will investigate
which factors predict this beneficial effect. These prog-
nostic factors may lead towards tailored treatments for
MS patients who suffer from cognitive problems.
An important strength of our study is that we use
functional brain network measures, such as functional
connectivity and nodal centrality, as an outcome vari-
able. These measures may help to explain treatment ef-
fects and may provide information on whether network
deterioration can be halted. Additionally, if functional
brain network measures at baseline predict treatment
outcomes, network analyses can be used as a prognostic
factor. We will also relate functional brain network mea-
sures to objective and subjective cognitive problems in
MS, which may help to understand the overlap and dis-
tinctiveness between these types of cognitive problems.
In summary, this study may help to unravel and treat
cognitive problems among MS patients.
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